| Document Date: 2014-11-06 23:49:39
Open Document File Size: 824,71 KBShare Result on Facebook
Company AEs / BOTOX / Allergan Australia Pty Ltd / Consumer Impact Statement There / Total services / / Country Australia / / Currency USD / / IndustryTerm injection site / placebo / health insurance / clinical management / literature search / conservative management / / MedicalCondition primary neurologic disorder / spina bifida / disease / Bladder infection / urinary retention / urge incontinence / urinary tract infection / urinary incontinence / stroke / overactive bladder syndrome / Parkinson's disease / Pain / neurologic disorder / Parkinson’s disease / multiple sclerosis / defined neurological illness / non-neurologic disease / MS / idiopathic overactive bladder / spinal cord injury / / MedicalTreatment antibiotics / / Organization Pharmaceutical Benefits Advisory Committee / Workers’ Compensation Regulatory Authority / Australian Medical Association / Medical Services Advisory Committee / Medicare / / Position anaesthetist / / Product Intravesical injection / / ProvinceOrState Mississippi / /
SocialTag |
Public Summary Document Application 1221 – Intravesical injection of BOTOX® (botulinum toxin type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) Sponsor/Applicant/s: